Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers (CS-PEDIA)

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Pediatric Solid Tumors

Study type: Observational

Funder types: Other

Identifiers

NCT06171971

8661

Details and patient eligibility

About

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of < 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Enrollment: 230 estimated patients

Sex: All

Ages: 1 to 22 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Patients of pediatric age up to 22 years included at the time of molecular analysis
• Histological carcinological diagnosis performed at HUS
• Carcinological follow-up performed at HUS
• Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
• Molecular analysis performed on tumor or blood samples
• Adult patients who do not object to the re-use of their personal data for medical research purposes
• Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.

Criteria for non-inclusion

• Molecular biology results not usable due to poor sample quality or insufficient genetic material
• Patients who have expressed their opposition to participate in the study
• Parental authority holders who have expressed their opposition to participate in the study